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Introduction: Children with persistent asthma may have diminished lung function in early
adulthood. In our previous study (‘CATO’) we showed preservation of lung function in asth-
matic children, during 2 years of treatment that was guided by airway hyperresponsiveness
(AHR). The aim of the present prospective follow up study was to investigate whether the pos-
itive effect of the AHR strategy on lung function had persisted beyond the duration of the
intervention study, after several years of usual care by paediatrician and general practitioner.
Methods: With a mean interval of 4.4 y after the last visit, 137 subjects (67% of the original
CATO population) participated in this follow-up study. Evaluation consisted of spirometry
(n Z 137), a methacholine challenge test (n Z 83), data on inhaled steroid treatment and
asthma exacerbations (n Z 137), and an asthma symptom diary during 6 weeks (n Z 90).
Results: At follow-up, lung function, % symptom-free days and exacerbation rates of both
treatment strategy groups was similar. The mean dose of inhaled corticosteroids had dimin-
ished from 550 mg/day at the end of CATO to 235 mg/day at follow-up. The decrease in AHR
measured at the end of CATO was maintained at follow-up for both treatment strategy groups.
Conclusion: The beneficial effect on lung function of 2 years treatment guided by AHR was lost
after 3e7 years of usual care. This suggests that an AHR-guided treatment strategy may need
to be sustained in order to preserve lung function.
ª 2013 Elsevier Ltd. All rights reserved.both, and these were analyzed separately.14 Subjects and/Introduction
Some longitudinal studies have shown that children with
persistent asthma have a lower lung function in young
adulthood.1,2 This seems independent of therapy with
inhaled corticosteroids (ICS).3 The outcome of asthma de-
pends on the duration of the disease,4,5 airflow obstruc-
tion,6,7 level of airway hyperresponsiveness (AHR),8 and
gender.1 Treatment with ICS reduces airway inflammation
and symptoms and improves lung function.9,10 Treatment
strategies that titrated the dose of ICS on the presence and
severity of eosinophilic airway inflammation showedmarked
reduction of asthma exacerbations11,12 and AHR.13 Long-
term effects of such treatment strategies have not been
reported. We previously documented preservation of lung
function in asthmatic children in whom treatment was
guided by AHR during a period of 2 years (CATO study clinical
trial number NCT00158834 at clinicaltrials.gov).14 This
benefit was especially seen in those children who had low
symptom scores and high levels of AHR. We hypothesized
that the benefit of a treatment strategy that takes AHR into
account would not persist beyond the duration of the
intervention, because treatment would again be solely
based on symptoms, and children may have bad perception.
For this purpose we performed a prospective follow up study
(clinical trial number NTC00441675 at clinicaltrials.gov) 3e7
years after the end of the CATO study.Methods
Patients
All patients who participated in the CATO study (n Z 206)
were asked to take part 3e7 years after they finished CATO.
At start of the CATO study, subjects were 6e16 y old and
had moderately severe allergic asthma. They were symp-
tomatic and/or had marked AHR.14 Thus, there were 3
predefined subgroups, characterized by symptoms, AHR oror parents (if children were younger than 18 years) gave
written informed consent. The study was approved by the
medical ethical committees of the participating centres.
Design
The mean interval between inclusion in the CATO study and
follow-upwas 4.4 years (range3e7 years).Originally, patients
were randomized and treated either on the basis of symptom
scores (reference strategy) or on symptoms and AHR (AHR
strategy).14 After the study, patients received usual care
based on guidelines of the Dutch Pediatric Respiratory
Group,15 largely corresponding to the GINA guidelines.16
Primary endpoint at follow-up was change in FEV1 (%pred)
from baseline at randomization. Secondary endpoints were
PD20, symptom scores and exacerbations, and ICS dose.
At follow-up, patients were seen twice. At the first visit,
spirometry was performed (FEV1, FVC and bronchodilator
response 20 min after inhalation of 400 mg salbutamol; Mas-
terscreen, Jaeger,Wu¨rzburg, Germany).17 Data on the use of
asthma medication were collected from pharmacists data
records. An asthma exacerbation was defined as a deterio-
ration of asthma requiring treatment with oral corticoste-
roids.14 Data on oral corticosteroid prescription were
collected from pharmacist records and patients or parents
reports. On the second follow-up visit 6 weeks later, the %
symptom-free days was determined, and a methacholine
challenge test was performed using the same dosimeter
protocol as in CATO.14 Short acting b-agonists were stopped
for 8 h, and long-acting b-agonists for 36 h before both visits.
Symptom scores
During the 6 weeks between the first and the second follow-
up visit children recorded asthma symptoms twice daily on
a diary card as used in CATO. Questions on cough, wheeze
and shortness of breath were each scored on a 0e3 point
scale, and the number of puffs of rescue b-agonists was
Hyperresponsiveness-guided asthma treatment 983recorded. A symptom-free day was defined as 24 h with
score 0 for cough, wheeze and shortness of breath.
Statistical analysis
Data at follow-up were compared with data of the same in-
dividuals during the CATO study period. As the use of age-
specific reference equations for spirometry might affect the
comparisons at follow-up that included children and young
adults, we additionally analyzed FEV1 normalized for a wide
age range.18 Comparison of categorical data was done with
the Chi-square test. Continuous data were compared be-
tween or within groups using the ManneWhitney and Wil-
coxon test, respectively. For the evaluation of exacerbation
rates, taking account of the duration of observation of indi-
vidual patients, Poisson regression analysis was used. The
highest dose of methacholine in the provocation tests was
1570 ug. If children had no 20% decrease of FEV1 at this dose,
the PD20 value was set at 1570 ug but was considered a right-
censored observation, i.e. the true PD20 value will be larger
than 1570 ug but remains unknown. Stata software (proce-
dure Cnreg), which allows for such censored data, was used
to evaluate the log-transformed PD20 outcomes. Profiles of
changes of FEV1 were calculated using repeated measure-
ments Anova, which allows for occasional missing values.
Correlation coefficients givenare Spearman’s. Data givenare
mean  sem, unless indicated otherwise. P Z 0.05 (two-
sided)was considered the limit of significance in all analyses.
Results
One hundred and eighty-nine children and adolescents of
the original CATO study population (nZ 206) were asked toTable 1 Characteristics of the children in the CATO-follow-up st
as measured at enrolment in the CATO14 intervention study. Da
(range).
Follow-up populat
Gender (%)
Male 74 (54)
Female 63 (46)
Age at enrolmenta (yrs) 10.4 (2.4)
Age at follow-up (yrs) 16.8 (2.4)
FEV1 (%pred) at enrolment 98.7(14.9)
FEV1/FVC (%) at enrolment 82.7 (8.4)
PD20 (mg methacholine) at enrolment 219 (0.8-> 1570)
% Symptom free days at enrolment 47.3 (37.2)
Treatment strategy (%)
AHR 76 (55)
Reference 61 (45)
Subgroup in CATO
AHR 58 (42)
Symptoms 32 (23)
AHR þ symptoms 47 (34)
Drop-out during CATO study
Yes 5 (4)
No 132 (96)
a At randomisation in the original CATO study.
b Upper limit of testing (1570 ug Z highest dose).participate, 17 could not be traced. One hundred thirty-
seven children (67% of the original study population)
participated in the first follow-up visit, 100 patients
completed both visits. The main reasons for nonparticipa-
tion were lack of time and other priorities. The distribution
of the participants over the original subgroups was the
same for both studies (CATO and CATO follow up). The
mean time interval between the last visit in the CATO study
and the first follow-up visit was 4.4 years (range 3e7); Age
and lung function of the population who participated
differed significantly from those of the children who did not
(Table 1).Lung function and AHR
FEV1 and postbronchodilator FEV1 were similar in children
from the AHR and reference strategy groups (97.5% (sd
14.7) and 98.0% (15.7), pZ 0.69). Postbronchodilator FEV1
was 105.9% (14.6) and 105.1% (16.0) for the AHR and
reference strategy groups (p Z 0.76). FEV1 changes from
initial CATO baseline were not different between the
treatment strategies: 1.6% (2.2) and 0.7% (1.7) for the
AHR and reference strategy groups (p Z 0.37). FEV1
changes since the end of the 2-years intervention were
1.4% (2.1) and þ0.6% (1.6), respectively (Fig. 1 A).
Changes in FEV1 at the first follow-up visit were similar for
the 3 subgroups (Fig. 1BeD). A borderline-significant dif-
ference in change in FEV1 was seen in the subgroup that had
benefited most from the AHR strategy initially (Fig. 1B).
Mean FEV1 change since end of CATO study period in this
subgroup was 6.0% (3.3) for the AHR strategy versus þ1.7%
(2.5) for the reference strategy (p Z 0.08). Repeated
analysis using reference equations for a wider age range18udy and those who did not participate in the follow-up study,
ta given are numbers (%) of patients, mean (sd), or median
ion n Z 137 No follow-up n Z 69 p-Value
43 (62) 0.32
26 (38)
11.8 (2.2) <0.001
18.2 (2.2) <0.001
92(12.8) 0.002
80.4 (9.2) 0.17
b 233 (0.8-> 1570)b 0.13
50.6 (35.9) 0.48
28 (41) 0.06
41 (59)
33 (48) 0.75
14 (20)
22 (32)
16 (23) <0.001
53 (77)
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Figure 1 Mean change from baseline of FEV1 (%pred) during the 2 years CATO intervention study
14 in patients who completed the
follow up study after the CATO trial, and at follow-up. Month 0 is time of enrolment, F.U. represents the follow-up assessment.
Error bars represent standard errors and solid and open symbols depict the AHR and reference strategy group, respectively. A: Total
group of 137 patients. B: Subgroup airway hyperresponsiveness, 58 patients. C: Subgroup symptoms, 32 patients. D: Subgroup with
airway hyperresponsiveness þ symptoms, 47 patients.
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Figure 2 Geometric mean PD20 values during the 2 years
984 M. Nuijsink et al.produced similar results, with no significant differences in
FEV1 at follow-up between treatment strategies in the total
population and in subgroups. No correlation was found
between FEV1 and time interval of follow-up visit or age at
follow-up. A significant correlation between FEV1 at start of
the original CATO study and FEV1 at follow-up existed
(r Z 0.45, p < 0.001). However, a lower FEV1 did not
correlate with FEV1 decline.
PD20 at follow-up was assessed in 83 patients (36 from
the AHR group and 47 from the reference strategy group).
The increase of PD20 during the CATO study was maintained
at follow-up for both treatment strategy groups (Fig. 2). No
differences between treatment strategy arms and sub-
groups were found. The mean change from baseline of PD20
at CATOeFU was 3.3 and 2.8 doubling doses for the AHR and
reference strategy, respectively (p Z 0.59).CATO intervention study14 in patients completing CATO-follow
up study and at CATO-follow-up study according to treatment
strategy. Month 0 is time of enrolment, F.U. represents the
follow-up assessment. Error bars represent standard errors and
solid and open symbols depict the AHR and reference strategy
group, respectively. Error bars represent standard errors.Symptoms and exacerbations
Ninety patients returned evaluable diary cards (at least 20
completed days in the 6 weeks period). The mean %
Hyperresponsiveness-guided asthma treatment 985symptom-free days was 63 (5) and 67 (4) for the AHR and
reference strategy groups, respectively (NS). The increase
in % symptom-free days from CATO baseline was maintained
at follow-up (Fig. 3).
During the CATO study 50 exacerbations requiring oral
steroids occurred in 33 patients. During the follow-up
years, 59 exacerbations were reported in 30 patients and
another 4 exacerbations in 4 patients were reported be-
tween the 2 follow-up visits. The mean annual exacerbation
rates were 0,26 in the year before- and 0.14 during the
CATO study, and 0.10 in the follow-up years. The exacer-
bation rates during the intervention and follow-up years did
not differ, and were significantly lower than before
entering CATO. Baseline FEV1 was inversely related to the
exacerbation rate: per 10% points increase in FEV1, the
exacerbation rate decreased by 0.84 (p Z 0.03).
Medication use
At follow-up, all but 5 children reported to have asthma
symptoms, although only 93 out of 137 (68%) still used ICS
with a mean daily reported dose of 248 mg fluticasone
equivalent. There was no difference in FEV1, AHR or
symptom scores in those with or without ICS at follow-up.
The ICS dose, based on pharmacy registrations, gradually
diminished over the years from 550 mg at the end of CATO to
235 mg at follow-up.
Discussion
We prospectively assessed the long-term effects of 2 years
of AHR-guided asthma treatment in children in whom we
previously found a better evolution of lung function as a
result of this intervention. After a mean interval of 4.4
years, range 3e7 years, the effect of AHR-guided treatment
on lung function was lost. Overall, AHR and symptom-free
days had remained at the same level as at the end of the 2-
year intervention, despite the use of much lower doses of
ICS and irrespective of the initial treatment strategy. We40
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Figure 3 Mean values of % symptom-free days at CATO14
enrolment, at the end of the 2-years CATO intervention study
in patients completing CATO-follow up study and at CATO-
follow-up study. (FU) error bars represent standard errors.
Solid and open symbols depict the AHR- and reference strategy
groups, respectively.speculate that this reflects the natural history of asthma,
which tends to improve during adolescence.1 The subgroup
of children with AHR and low symptom scores at baseline
benefited most from the AHR strategy in the CATO study.
This benefit was also lost at follow-up.
To our knowledge this is the first study which focuses on
long-term effects of a phenotype-specific treatment strat-
egy. Few studies have examined the persistence of effects
of treatment strategies.19 Recent data from the CAMP
follow-up study showed that the positive effects of treat-
ment with ICS on AHR, lung function and asthma control
had disappeared 4 years after discontinuation of ICS.20
Waalkens et al. reported similar findings already within 6
months after discontinuation of inhaled corticosteroids.21
Contrary to the data of the CAMP follow-up study our
data show that improvement in AHR and reduction of
asthma exacerbations were maintained at the level
reached during the intervention study, and we speculate
that this is because of the continuous treatment with ICS.
Contrary to the CAMP study the majority of children in our
study continued their ICS.
That the subgroup with low symptom perception, that
initially improved most from the AHR strategy, showed no
lasting benefit beyond the duration of the intervention
study is remarkable. One could imagine that participation
in a 2-year intervention study with regular assessments of
AHR and lung function might well improve symptom
perception, and that this could specifically help children in
the subgroup with low symptom scores despite AHR. This
was apparently not the case, suggesting that there was no
long-term effect of 2 years of AHR-guided treatment on
symptom perception.
As can be expected in an adolescent population, a sub-
stantial number of the original study population could not
be persuaded to co-operate in the follow-up. Our results
may therefore have been biased by selection. Children in
the follow-up study were younger and had higher FEV1
values than those of the original study population. Adoles-
cence, with a concomitant loss of interest and low priority
of attending, may well have accounted for the younger age
of those who participated at follow-up. We think it is un-
likely that high FEV1 values interact with the willingness to
participate. However, as children who did not participate
indeed had a lower baseline FEV1, such an effect could have
influenced our results.6 It might be that children with lower
FEV1 benefited more from an intensive treatment strategy.
It could be argued that expressing lung function as % pre-
dicted at follow-up becomes problematic when separate
adult and paediatric reference equations for spirometry are
used. We think that this has not affected our findings, as
additional analyses using reference equations for a wide
age range produced similar results.18
What could be the impact of our finding for clinical
practice? The long-term evolution of lung function suggests
that an AHR-guided treatment strategy may need to be
sustained for longer than 2 years in order to preserve lung
function. In view of the relatively low ICS doses at the end
of the intervention, such a strategy would seem to be safe.
It remains to be shown that such a strategy would be
feasible and has the desired long-term effects.
In conclusion, we found that the beneficial effect on
lung function of 2 years’ asthma treatment guided by AHR
986 M. Nuijsink et al.was lost after 5 years of usual care, based on international
guidelines. It remains to be shown if continuation of the
experimental treatment strategy could have maintained
the initial effect or might have further improved lung
function.
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